These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 30203114)

  • 1. Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases.
    Cai B; Sun S; Li Z; Zhang X; Ke Y; Yang J; Li X
    Hum Genet; 2018 Sep; 137(9):679-688. PubMed ID: 30203114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced Pluripotent Stem Cells and Genome-Editing Tools in Determining Gene Function and Therapy for Inherited Retinal Disorders.
    Benati D; Leung A; Perdigao P; Toulis V; van der Spuy J; Recchia A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.
    Burnight ER; Gupta M; Wiley LA; Anfinson KR; Tran A; Triboulet R; Hoffmann JM; Klaahsen DL; Andorf JL; Jiao C; Sohn EH; Adur MK; Ross JW; Mullins RF; Daley GQ; Schlaeger TM; Stone EM; Tucker BA
    Mol Ther; 2017 Sep; 25(9):1999-2013. PubMed ID: 28619647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of CRISPR/Cas9 in retinal degenerative diseases.
    Peng YQ; Tang LS; Yoshida S; Zhou YD
    Int J Ophthalmol; 2017; 10(4):646-651. PubMed ID: 28503441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.
    Burnight ER; Giacalone JC; Cooke JA; Thompson JR; Bohrer LR; Chirco KR; Drack AV; Fingert JH; Worthington KS; Wiley LA; Mullins RF; Stone EM; Tucker BA
    Prog Retin Eye Res; 2018 Jul; 65():28-49. PubMed ID: 29578069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases.
    Wiley LA; Burnight ER; Songstad AE; Drack AV; Mullins RF; Stone EM; Tucker BA
    Prog Retin Eye Res; 2015 Jan; 44():15-35. PubMed ID: 25448922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized therapeutic strategies for patients with retinitis pigmentosa.
    Zheng A; Li Y; Tsang SH
    Expert Opin Biol Ther; 2015 Mar; 15(3):391-402. PubMed ID: 25613576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research progress of CRISPR-Cas9 system for gene therapy].
    Zhan C; Xia X
    Sheng Wu Gong Cheng Xue Bao; 2016 Jul; 32(7):861-869. PubMed ID: 29019208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
    Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
    Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells.
    Bassuk AG; Zheng A; Li Y; Tsang SH; Mahajan VB
    Sci Rep; 2016 Jan; 6():19969. PubMed ID: 26814166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa.
    Hu S; Du J; Chen N; Jia R; Zhang J; Liu X; Yang L
    Invest Ophthalmol Vis Sci; 2020 Apr; 61(4):31. PubMed ID: 32330228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Genome Editing by CRISPR/Cas9-Mediated Strategy to Cure Genetic Disorders in Humans: Guide for Molecular Surgeons.
    Ergoren MC; Idlibi R
    Crit Rev Eukaryot Gene Expr; 2019; 29(5):387-399. PubMed ID: 32421996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 genome surgery for retinal diseases.
    Xu CL; Park KS; Tsang SH
    Drug Discov Today Technol; 2018 Aug; 28():23-32. PubMed ID: 30205877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome Surgery and Gene Therapy in Retinal Disorders.
    Chan L; Mahajan VB; Tsang SH
    Yale J Biol Med; 2017 Dec; 90(4):523-532. PubMed ID: 29259518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene editing prospects for treating inherited retinal diseases.
    Benati D; Patrizi C; Recchia A
    J Med Genet; 2020 Jul; 57(7):437-444. PubMed ID: 31857428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.